About The Episode

Welcome to another episode of automated, the podcast that explores the impact of technology on jobs, with your host Marc Verbenkov. 

Although in previous episodes I haven’t spoken much about the impact technology and automation has had on the biomedical industry, it is certainly an interesting topic for the podcast especially as the application of new medical technology is going to change the way we deal with public health over the next few decades more than ever before. So with this in mind I’m happy to have on my guest this week to discuss automation and how it is impacting drug discovery. 

We discuss the current state of drug discovery, how Arctoris and automation solves a number of challenges, how Covid has impacted the industry, the impact on jobs, and what the future for drug discovery might look like.

About The Guest

Martin-Immanuel Bittner is the CEO of Arctoris, the world’s first fully automated drug discovery platform that he cofounded in Oxford. He graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. Martin has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences in 2018.

 Get in touch with Martin:
             Linkedin: https://www.linkedin.com/in/martinimmanuelbittner/

Additional Notes:
Arctoris Website: https://www.arctoris.com/
Arctoris Medium: https://arctoris.medium.com/